ME/CFS is diagnosed from a characteristic symptom pattern and reduced function—not a positive blood test. The assessment also checks for treatable conditions that could explain or accompany those symptoms.
- Clinical diagnosis requires a characteristic symptom pattern; no routine blood test confirms or excludes ME/CFS.
- Post-exertional malaise often begins 12–48 hours after activity and can last days or longer; ordinary tiredness after exercise is different.
- US diagnostic criteria require substantial impairment lasting more than 6 months, fatigue, PEM, unrefreshing sleep, and cognitive impairment or orthostatic intolerance.
- UK NICE criteria permit diagnosis after 3 months when all 4 core symptom groups are present and another condition does not explain them.
- Simptomu biežums under the National Academy of Medicine framework should be at least half the time, with moderate or greater intensity.
- Dzelzs deficīts can contribute to fatigue before anemia develops; ferritin below 15 ng/mL strongly supports depleted stores in otherwise healthy adults.
- Orthostatic assessment may include up to 10 minutes of supervised standing; POTS requires more than a single high pulse reading.
- Nākamie soļi include energy management, treatment of accompanying conditions, and planned follow-up—not fixed weekly increases in exercise.
How is ME/CFS diagnosed in a clinical appointment?
Chronic fatigue syndrome diagnosis is clinical: clinicians identify post-exertional malaise, substantial loss of everyday function, unrefreshing sleep, and cognitive or orthostatic symptoms, then assess alternative explanations. No routine blood test confirms ME/CFS. The National Academy of Medicine framework requires more than 6 months of impairment; UK NICE permits diagnosis after 3 months.
The assessment has 2 parallel tracks: establishing whether the ME/CFS pattern is present and investigating other plausible causes. A normal panel completes neither track by itself; equally, finding a small laboratory abnormality does not automatically explain a profound decline in function or delayed crashes after ordinary activity.
A useful first appointment documents 3 anchors: what you could do before illness, what you can do now, and what happens afterward. Someone who still completes a work shift may nevertheless have substantial impairment if working consumes all available capacity and leaves them unable to cook, shower, or participate in family life.
I’m Thomas Klein, MD, Chief Medical Officer at Kantesti, and I would start with those functional questions rather than order an indiscriminate panel. Our organizācija un mērķis explain the distinction between interpreting laboratory information and making a diagnosis that requires a clinical history, examination, and sometimes several appointments.
Kantesti ir AI asins analīžu analizators that can help explain results used to investigate alternative causes of fatigue, but it cannot establish the required symptom pattern. As of October 23, 2026, this guide draws on NICE’s 2021 guideline and the National Academy of Medicine’s 2015 framework—not a purported new 2026 diagnostic blood test.
What are the National Academy of Medicine diagnostic criteria?
The 2015 National Academy of Medicine criteria require substantial reduction in pre-illness activity lasting more than 6 months, accompanied by fatigue, post-exertional malaise, and unrefreshing sleep. At least 1 additional feature—cognitive impairment or orthostatic intolerance—is required. Symptoms should occur at least half the time with moderate, substantial, or severe intensity.
The fatigue must be of new or definite onset, not lifelong, not the result of ongoing excessive exertion, and not substantially relieved by rest. These qualifications distinguish the syndrome from simply feeling exhausted after an unusually demanding month; the 6-month requirement does not mean care should be withheld until the clock runs out.
The National Academy of Medicine report, published under the Institute of Medicine name, emphasizes symptom frequency and severity rather than a checklist of occasional experiences (Institute of Medicine, 2015). Having 1 bad night and occasional forgetfulness is not equivalent to recurrent, function-limiting symptoms throughout an otherwise typical week.
Consider an illustrative adult who has reduced paid work from 40 to 20 hours weekly, experiences delayed symptom worsening after meetings, and wakes unrefreshed despite adequate sleep opportunity. Cognitive slowing could satisfy the additional symptom domain; dizziness on standing would strengthen the assessment but is not mandatory under this framework.
A useful first laboratory assessment supports the search for competing explanations; it does not replace these clinical requirements. Bring a medication list and a brief account of symptom frequency over 2 representative weeks, including days when you deliberately did very little to avoid a crash.
Why do UK and US diagnostic timelines differ?
NICE NG206 allows ME/CFS diagnosis after 3 months of persistent symptoms when another condition does not explain them; the National Academy of Medicine framework requires more than 6 months of impaired activity. NICE requires all 4 core groups, including cognitive difficulties, whereas the US framework allows cognitive impairment or orthostatic intolerance.
NICE advises suspecting ME/CFS after at least 6 weeks of symptoms in adults or 4 weeks in children and young people, provided the characteristic pattern and reduced function are present (NICE, 2021). Suspicion triggers investigation and support; it is not the same as a confirmed diagnosis or a reason to stop considering alternatives.
The 3-month and more-than-6-month thresholds are operational guideline choices, not evidence that a biological switch flips on a particular date. A clinician should record which framework they are using so that a later specialist, insurer, or school understands why the diagnosis was made and which symptoms were documented.
Children need an assessment of attendance, learning, social participation, and basic daily activities—not merely an adult questionnaire scaled down. A child attending school for 2 mornings weekly may appear outwardly engaged while needing prolonged recovery afterward; parents’ observations and the child’s own account can reveal different parts of the pattern.
Mūsu skaidrojums par pediatric interpretation limits addresses why age-specific laboratory ranges require care, but laboratory interpretation cannot replace pediatric assessment. Support at school and advice about avoiding symptom-provoking overexertion can begin during the initial 4-week or 6-week suspicion period, before diagnostic confirmation.
How do clinicians recognize post-exertional malaise?
Post-exertional malaise, or PEM, is worsening of the illness after activity that previously would have been tolerated. Physical, cognitive, emotional, or social exertion can trigger it. Symptoms often worsen 12–48 hours later and may persist for days or longer, although onset and recovery vary considerably between patients.
PEM is more than muscle soreness or being pleasantly tired after exercise. A 20-minute conversation might be followed by intensified cognitive problems, sleep disturbance, pain, flu-like feelings, or reduced upright tolerance; the diagnostic clue is a disproportionate, multisymptom deterioration rather than the fact that activity used energy.
Ask about the day after the day after. A patient may feel reasonably capable during a supermarket trip yet spend the next 2 days recovering, so asking only whether they can shop misses the cost; repeated activity can also produce overlapping crashes that obscure any single trigger.
A 7–14-day activity-and-symptom diary can document the pattern without deliberately provoking it. Record the type of activity, approximate duration, immediate response, next-day response, and recovery time; our timeline interpretation guide explains a separate issue—why laboratory changes also need context rather than attribution to one event.
Two-day cardiopulmonary exercise testing is not required for routine ME/CFS diagnosis and can provoke substantial symptom worsening. It may have a role in selected specialist or disability assessments, but a clinician should discuss risks, practical benefit, and alternatives; a patient does not need to demonstrate a crash by pushing through a test.
What counts as substantial impairment of daily function?
Substantial impairment means a sustained reduction from the person’s own pre-illness capacity, not failure to meet an arbitrary step count. Clinicians assess work, education, personal care, household activity, and social participation. There is no universally required 50% reduction threshold in the National Academy of Medicine or NICE diagnostic framework.
Compare like with like over 2 periods: before illness and a representative current week. A former full-time worker managing 10 hours weekly has an obvious decline, but a caregiver maintaining essential tasks by abandoning leisure, relying on help, and resting between chores may have impairment that employment statistics completely miss.
Activity counts can underestimate illness when patients have already adapted successfully. Someone taking 3,000 steps daily without a conspicuous crash may be staying within a restricted energy limit; the absence of recent PEM during strict pacing does not establish that the underlying exertional intolerance has disappeared.
Clinicians also separate fatigue from weakness, breathlessness, and sleepiness because these suggest different investigations. Difficulty lifting a cup, falling asleep involuntarily, and feeling depleted after a shower are 3 different descriptions; asking the patient to demonstrate or describe the limitation can prevent an unhelpfully broad label of tiredness.
Treatable contributors still deserve attention when the ME/CFS pattern is convincing. For example, iron depletion before anemia can add to limited capacity, particularly with heavy menstrual loss; improvement after correcting low iron does not necessarily eliminate a separate pattern of delayed PEM and unrefreshing sleep.
How is unrefreshing sleep assessed without missing a sleep disorder?
Unrefreshing sleep means waking without expected restoration, even when sleep opportunity appears adequate. It is required by both major ME/CFS frameworks, but it does not exclude obstructive sleep apnea, insomnia, restless legs syndrome, or another sleep disorder. Sleeping 8–9 hours is not proof that sleep quality is normal.
A sleep history should cover bedtime, wake time, awakenings, snoring, witnessed breathing pauses, restless legs, and daytime sleep attacks. A 2-week sleep diary often clarifies whether the problem is insufficient opportunity, disrupted sleep, an irregular rhythm, or a persistent lack of restoration despite a reasonably consistent schedule.
Sleepiness and fatigue overlap, but they are not interchangeable. Someone who unintentionally falls asleep during a 15-minute quiet activity needs assessment for excessive daytime sleepiness; someone who remains awake but feels cognitively and physically depleted may need a different pathway, although both problems can occur together.
Mūsu sleep-study diagnostic pathway explains why narcolepsy testing requires careful preparation and specialist interpretation. Neither a normal overnight study nor a normal multiple sleep latency test rules out ME/CFS; these tests answer questions about sleep physiology, not the entire clinical syndrome.
Treat an identified sleep disorder and reassess the remaining symptom pattern rather than assuming 1 diagnosis explains everything. If effective apnea treatment improves alertness but a short outing still triggers a 48-hour multisymptom deterioration, the clinician should continue evaluating PEM and function instead of declaring the fatigue assessment finished.
Which cognitive symptoms support an ME/CFS diagnosis?
ME/CFS cognitive symptoms can include slowed processing, reduced attention, word-finding problems, and difficulty holding information in mind. They may worsen after exertion or while upright. New cognitive difficulties occurring alongside PEM differ from lifelong attention problems; a normal brief screening score does not necessarily capture fluctuating impairment.
Ask for 2 concrete examples rather than accepting brain fog as a complete description. Losing track of a familiar recipe and needing repeated rereading of a short email reveal different limitations; examples also help clinicians distinguish processing difficulty from a language deficit, severe sleepiness, medication effects, or progressive neurological disease.
The conditions of testing matter. A 10-minute assessment in a quiet room after rest may look normal despite major difficulties during a noisy workday; clinicians can document this mismatch without asserting that every complaint requires formal neuropsychological testing or that a normal test means the symptoms are imagined.
Lifelong distractibility requires a developmental history, whereas new slowing after illness requires assessment of onset and associated symptoms. Our discussion of lifelong attention versus brain fog explains why 1 adult screening questionnaire cannot reliably resolve that distinction or establish the cause of a recent decline.
Sudden speech disturbance, new one-sided weakness, or acute confusion requires urgent assessment rather than attribution to ME/CFS. Gradual but progressive deterioration over 3–6 months also warrants reconsideration of alternatives; familiar brain fog should not become a catch-all explanation for a genuinely new neurological symptom.
How are orthostatic intolerance and POTS evaluated?
Orthostatic intolerance causes symptoms while upright that improve with sitting or lying down, such as lightheadedness, palpitations, nausea, or cognitive worsening. Clinicians may measure pulse and blood pressure during a supervised stand lasting up to 10 minutes. POTS is one possible diagnosis, not a requirement for ME/CFS.
Adult POTS criteria include a sustained heart-rate rise of at least 30 beats/minute within 10 minutes upright; the threshold is at least 40 beats/minute for ages 12–19. The diagnosis also requires frequent orthostatic symptoms for at least 3 months, no significant orthostatic hypotension, and no other explanation for the tachycardia (Raj et al., 2022).
A blood-pressure fall of at least 20 mmHg systolic or 10 mmHg diastolic within 3 minutes of standing suggests classic orthostatic hypotension. These thresholds describe different physiological patterns; a single smartwatch pulse spike cannot determine which pattern is present or whether medication, dehydration, anemia, or thyroid disease is responsible.
Morning testing may reveal a stronger heart-rate response, and results can vary between visits. If a 10-minute stand is intolerable, stop and adapt the assessment rather than insisting on completion; people with severe ME/CFS may need shorter measurements, specialist advice, or home-based arrangements that minimize symptom worsening.
Mūsu palpitation assessment guide covers laboratory contributors, but an ECG and clinical examination may also be needed. Salt, fluid, compression, or medication advice should be individualized; a blanket instruction to drink 3 liters daily is inappropriate for someone with heart failure, kidney disease, or fluid restrictions.
Why can’t a routine blood test confirm ME/CFS?
No routine blood test has established diagnostic accuracy sufficient to confirm or rule out ME/CFS. Normal full blood count, thyroid function, ferritin, or inflammatory markers do not exclude it. Research findings in immune function, metabolism, and other systems are not interchangeable with a validated test for an individual patient.
A useful diagnostic biomarker must distinguish the target condition from realistic alternatives, not merely separate 2 small groups of patients and healthy volunteers. It also needs reproducible performance across laboratories and populations; an intriguing research signal may fail when compared with sleep disorders, long COVID, autoimmune disease, or medication-related fatigue.
Sensitivity and specificity depend on the intended use and the population tested. Even an apparently promising 90% specificity can create many false positives when used in a low-prevalence population; without independently validated clinical performance, a commercial score should not replace documented PEM, functional decline, and a proper differential assessment.
Kantesti ir AI asins analīžu rezultātu platforma that explains laboratory findings; it does not turn normal results into a positive ME/CFS diagnosis. Our tehniskie un klīniskie standarti should be considered separately from disease-specific validation: interpreting a thyroid result accurately is not evidence that an engine can diagnose ME/CFS.
Repeatedly ordering the same normal panel every 4 weeks rarely resolves an unchanged clinical question. Retesting becomes more useful when symptoms change, an abnormality needs follow-up, a treatment could affect results, or a new examination finding raises a different hypothesis; otherwise, the next step may be better history-taking rather than more samples.
Which baseline tests help assess alternative causes of fatigue?
Baseline investigations look for alternative or accompanying conditions—not an ME/CFS signature. NICE lists full blood count, kidney and liver tests, thyroid function, ESR or plasma viscosity, CRP, calcium, phosphate, HbA1c, ferritin, celiac screening, creatine kinase, and urinalysis. Additional tests, including B12, folate, vitamin D, or 9 a.m. cortisol, depend on clinical judgment.
Ferritin below 15 ng/mL strongly supports depleted iron stores in otherwise healthy adults, but inflammation can raise ferritin and conceal deficiency. The iron-study interpretation guide explains why transferrin saturation and clinical context may be needed; one result should not be treated as a universal threshold for every patient.
Thyroid interpretation usually begins with TSH, with free T4 added or interpreted according to the clinical situation. A mildly high TSH with normal free T4 does not automatically explain severe PEM; our tiroksīna un TSH skaidrojumā helps distinguish overt dysfunction from a result that may require repeat testing.
B12 assessment becomes particularly relevant with dietary restriction, malabsorption risk, neuropathic symptoms, or macrocytosis; neurological deficiency can occur without anemia. A total B12 of 200–300 pg/mL may be considered borderline in some laboratories, and our robežlīmeņa B12 izmeklēšanas vadlīnijas explains why assay ranges and confirmatory testing matter.
Kantesti can help organize these results alongside their units, laboratory intervals, and previous values, but the ordering clinician decides what is appropriate. Tell them about supplements, recent illness, and medications before the appointment; a 9 a.m. cortisol, for example, addresses selected adrenal concerns and is not a general test for stress or an ME/CFS confirmation test.
How do clinicians decide whether another diagnosis explains the symptoms?
Alternative diagnoses are assessed through history, examination, and targeted investigations, with attention to whether they explain the whole symptom pattern. Anemia, thyroid disease, sleep disorders, medication effects, cardiopulmonary disease, autoimmune conditions, and depression can cause fatigue. More than 1 diagnosis may be present, so finding a contributor does not automatically exclude ME/CFS.
A medication review should include prescriptions, over-the-counter products, supplements, alcohol, and other substances, with changes over the preceding 3 months. Sedating antihistamines, some pain medicines, and other drugs may impair alertness; beta-blockers can change pulse responses, complicating interpretation of an upright assessment without necessarily explaining delayed PEM.
Autoimmune testing becomes more useful when fatigue accompanies specific findings such as persistent joint swelling, photosensitive rash, Raynaud symptoms, or marked dryness. Our dryness and systemic symptom guide explains one relevant pathway; fatigue alone generally provides a weaker reason for broad antibody screening than fatigue plus 2 objective or characteristic features.
Depression deserves respectful assessment and treatment when present, but it should not be inferred from reduced activity alone. A person who wants to participate but develops a 2-day crash afterward presents a different clinical question from reduced motivation; mood symptoms and ME/CFS can coexist, and neither should erase the other.
New weight loss, persistent fever, abnormal examination findings, or progressive objective weakness shifts the differential away from uncomplicated fatigue. Ask whether an alternative explains 3 elements together—onset, symptom pattern, and trajectory—then reassess after appropriate treatment rather than assuming that a borderline laboratory result has settled the diagnosis.
When do infection and autoimmune antibody tests help?
Infection and autoimmune tests help when exposure history, examination, or specific symptoms justify them. They do not confirm ME/CFS simply because they are positive. EBV IgG commonly reflects previous infection, while a positive ANA can occur without systemic autoimmune disease; interpretation requires the antibody pattern and the clinical question.
EBV antibody testing distinguishes patterns of exposure; it is not a meter of ongoing fatigue severity. Our EBV antivielu atbilstības rokasgrāmata explains VCA IgM, VCA IgG, and EBNA; more than 90% of adults have evidence of previous EBV infection, so a positive IgG alone is unsurprising.
ANA interpretation depends on method, titer, pattern, and compatible clinical findings. A result such as 1:80 does not establish lupus or explain PEM by itself; the ANA interpretation basics explain why a screening result may require no additional testing in one patient but targeted evaluation in another.
Long COVID and ME/CFS can overlap, particularly when delayed exertional worsening, unrefreshing sleep, and cognitive or orthostatic symptoms persist. Not everyone with long COVID meets ME/CFS criteria, and someone with 3 months of post-COVID symptoms may meet NICE’s timeline before meeting the National Academy of Medicine duration requirement.
Broad panels for multiple pathogens can create false leads when exposure risk is low and positive antibodies merely show past contact. Targeted testing should answer a specific question—such as a compatible illness after a tick exposure—rather than search for any positive result that might justify months of antimicrobial treatment without evidence of active infection.
What should happen after ME/CFS is suspected or diagnosed?
Next steps include individualized energy management, treatment of accompanying conditions, and planned reassessment. Support should begin before every diagnostic uncertainty is resolved. NICE advises against programs using fixed incremental increases in activity or exercise, including graded exercise therapy; the goal is to avoid provoking PEM, not meet a predetermined weekly exercise target.
Energy management includes physical, cognitive, emotional, and social activity—not just steps or workouts. Splitting a 20-minute task into shorter parts may help, but there is no universal safe interval; decisions should follow the patient’s response, including symptoms appearing the following day rather than only during the task.
A practical follow-up plan names 3 things: who coordinates care, which symptoms or results will be reassessed, and when to seek earlier help. Patients with severe or very severe ME/CFS may need home visits, reduced sensory stimulation, mobility support, and help accessing nutrition; attendance at a distant clinic can itself be a major exertional load.
Supplements should address a demonstrated need or a carefully discussed symptom goal, not a promise to cure ME/CFS. Our lab-guided fatigue supplement discussion separates deficiency treatment from unsupported combinations; adding 5 products at once also makes side effects and any benefit harder to interpret.
Chest pain, severe breathlessness, fainting with concerning features, sudden neurological symptoms, or inability to maintain fluids requires urgent assessment rather than waiting for a routine follow-up. A new decline over 24–48 hours should be judged on its features and severity; a previous ME/CFS diagnosis does not protect someone from an unrelated acute illness.
Where does lab interpretation fit in the next-step care plan?
Lab interpretation can support the search for treatable contributors, but a clinician remains responsible for ME/CFS diagnosis. A useful next-step packet contains 3 components: a symptom-and-function summary, relevant results with dates and units, and a medication list. It should make the appointment easier—not replace history-taking or examination.
Kantesti ir ar AI balstīts asins analīzes rīks that can explain uploaded laboratory reports and organize trends for discussion with a healthcare professional. Our AI tehnoloģijas paskaidrojums describes the interpretation workflow; neither a report summary nor a risk score substitutes for documenting PEM and the applicable 3-month or more-than-6-month timeline.
Privacy matters when sharing a report that contains identifiers, dates of birth, or information about relatives. Review our informāciju par privātumu un datiem before uploading, and share only information you are authorized to provide; keeping 1 concise, relevant record is often more useful than circulating an entire medical history.
My practical advice as Thomas Klein, MD, is to ask 3 questions: Which diagnostic framework applies, what alternatives still need assessment, and what support can start now? Information about our medicīniskās konsultēšanas komandu provides organizational context, but your own clinician must assess your symptoms and arrange a workable follow-up plan.
The 2 repository guides listed below are related educational publications, not peer-reviewed validation of an ME/CFS biomarker. The complement-testing clinical context concerns selected autoimmune questions. The Izglītojošs ceļvedis par Nipah diagnostiku concerns a separate acute illness and is not a routine investigation for chronic fatigue.
Research publications and evidence boundaries
The 2 Zenodo records are presented as supplementary educational resources, separate from the directly relevant diagnostic references below. ResearchGate and Academia.edu links are title searches, not claims that verified copies exist on those services; neither repository publication supports diagnosing ME/CFS from routine laboratory results.
Bieži uzdotie jautājumi
Vai pastāv asins analīze hroniska noguruma sindroma noteikšanai?
Nav rutīnas asins analīzes, kas apstiprinātu vai izslēgtu ME/CFS. Ārsti diagnosticē šo stāvokli, pamatojoties uz raksturīgu simptomu kopumu, ikdienas funkcionēšanas traucējumiem un alternatīvu skaidrojumu izvērtēšanu. Nacionālās medicīnas akadēmijas vadlīniju ietvarā nepieciešami traucējumi ilgāk nekā 6 mēnešus, savukārt NICE ļauj noteikt diagnozi pēc 3 mēnešiem. Asins analīzes var atklāt veicinošus faktorus, piemēram, anēmiju, vairogdziedzera slimību vai dzelzs deficītu, taču normāli rezultāti neizslēdz ME/CFS.
Kādi ir galvenie ME/CFS diagnostikas kritēriji?
Nacionālās medicīnas akadēmijas kritēriji paredz būtiski samazinātu aktivitāti salīdzinājumā ar stāvokli pirms slimības, kas ilgst vairāk nekā 6 mēnešus, nogurumu, slodzes izraisītu pašsajūtas pasliktināšanos un neatjaunojošu miegu. Nepieciešami arī kognitīvi traucējumi vai ortostatiska nepanesība. Simptomiem jāizpaužas vismaz pusi laika ar vidēju vai lielāku intensitāti. NICE izmanto 3 mēnešu diagnostikas termiņu un līdztekus citām galvenajām simptomu grupām pieprasa kognitīvas grūtības.
Kā es varu zināt, vai man ir slodzes izraisīts nespēks?
Pēcslodzes pašsajūtas pasliktināšanās ir nesamērīga simptomu pastiprināšanās pēc fiziskas, kognitīvas, emocionālas vai sociālas aktivitātes. Pasliktināšanās bieži sākas pēc 12–48 stundām un var ilgt vairākas dienas vai ilgāk, lai gan laiks var atšķirties. Aktivitāšu un simptomu dienasgrāmata 7–14 dienu garumā var palīdzēt ārstam noteikt šo saistību, apzināti neizraisot stāvokļa saasinājumu. Parasta muskuļu jutība pēc fiziskas slodzes vai nogurums vien neapstiprina PEM vai ME/CFS diagnozi.
Vai ME/CFS var diagnosticēt pirms sešu mēnešu perioda?
ME/CFS var diagnosticēt pēc 3 mēnešiem saskaņā ar NICE NG206, ja saglabājas nepieciešamais simptomu kopums un to neizskaidro cita slimība. Nacionālās medicīnas akadēmijas ietvars paredz, ka aktivitātes ierobežojums ilgst vairāk nekā 6 mēnešus. NICE iesaka apsvērt šo diagnozi pēc 6 nedēļām pieaugušajiem vai 4 nedēļām bērniem un jauniešiem. Novērtēšanu, praktisku atbalstu un ieteikumus izvairīties no pārmērīgas slodzes, kas izraisa simptomus, nevajadzētu atlikt līdz diagnozes apstiprināšanai.
Vai POTS nozīmē, ka man ir ME/CFS?
POTS pati par sevi nenosaka ME/CFS diagnozi, lai gan šie stāvokļi var pastāvēt vienlaikus. POTS diagnostikas kritēriji pieaugušajiem ietver ilgstošu sirdsdarbības ātruma palielināšanos vismaz par 30 sitieniem minūtē 10 minūšu laikā, atrodoties vertikālā stāvoklī, biežus ortostatiskus simptomus vismaz 3 mēnešus un citu iespējamo cēloņu izslēgšanu. Sirdsdarbības ātruma slieksnis 12–19 gadu vecumā ir vismaz 40 sitienu minūtē. ME/CFS gadījumā nepieciešams atsevišķi izvērtēt simptomus un funkcionēšanu, tostarp slodzes izraisītu nespēku un miegu, pēc kura cilvēks nejūtas atpūties.
Vai man vairāk sportot, gaidot ME/CFS novērtējumu?
0. Neizmantojiet fiksētus slodzes palielināšanas plānus, lai mēģinātu pārvarēt iespējamu pēcs slodzes nespēku. NICE neiesaka ME/CFS gadījumā izmantot programmas, kuru pamatā ir iepriekš noteikts pakāpenisks aktivitāšu vai fizisko vingrinājumu apjoma palielinājums. Novērojiet, kā aktivitātes ietekmē simptomus nākamo 24–48 stundu laikā, un pārrunājiet ar ārstu individuāli pielāgotu enerģijas pārvaldību. Tas nenozīmē, ka ikvienam jāizvairās no jebkādas kustēšanās; pacientiem būtiski atšķiras gan panesamais aktivitāšu līmenis, gan nepieciešamais atbalsts.
Vai dzelzs deficīts vai depresija var izslēgt ME/HNS?
Dzelzs deficīts vai depresija automātiski neizslēdz ME/CFS, jo var būt vairāk nekā viens stāvoklis. Feritīna līmenis zem 15 ng/mL stingri liecina par izsīkušiem dzelzs krājumiem citādi veseliem pieaugušajiem, lai gan interpretācija mainās iekaisuma un citu apstākļu gadījumā. Ārsti ārstē konstatētos veicinošos faktorus un atkārtoti izvērtē, vai tie izskaidro visu simptomu kopumu, tostarp aizkavētu postslodzes nespēku. Simptomu saglabāšanās pēc ārstēšanas prasa klīnisku izvērtējumu, nevis pieņēmumu, ka kāda no diagnozēm izskaidro visu.
Iegūstiet AI vadītu asins analīžu analīzi jau šodien
Pievienojieties vairāk nekā 2 miljoniem lietotāju visā pasaulē, kuri uzticas Kantesti tūlītējai, precīzai laboratorijas analīžu interpretācijai. Augšupielādējiet savas asins analīzes rezultātus un dažu sekunžu laikā saņemiet visaptverošu 15,000+ biomarķieru interpretāciju.
📚 Atsauces pētniecības publikācijas
Kleins, T., Mičels, S., un Vēbers, H. (2026). C3 C4 komplementa asins analīzes un ANA titra ceļvedis. Kantesti AI Medicīnas pētījumi.
Kleins, T., Mičels, S., un Vēbers, H. (2026). Nipah vīrusa asins analīze: agrīnas noteikšanas un diagnostikas ceļvedis 2026. gadam. Kantesti AI Medicīnas pētījumi.
📖 Ārējās medicīniskās atsauces
Nacionālais veselības un aprūpes izcilības institūts (NICE) (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management. NICE guideline NG206.
Institute of Medicine (2015). Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press.
Raj SR, Fedorowski A, Sheldon RS (2022). Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ.
⚕️ Medicīniskā atruna
Šis raksts ir paredzēts tikai izglītojošiem nolūkiem un nav medicīnisks padoms. Vienmēr konsultējieties ar kvalificētu veselības aprūpes speciālistu, lai pieņemtu lēmumus par diagnostiku un ārstēšanu.
E-E-A-T uzticēšanās signāli
Pieredze
Ārstu vadīta klīniskā laboratorijas interpretācijas darbplūsmu pārskatīšana.
Ekspertīze
Laboratorijas medicīnas fokuss uz to, kā biomarķieri uzvedas klīniskā kontekstā.
Autoritāte
Sagatavojis Dr. Thomas Klein, pārskatījusi Dr. Sarah Mitchell un prof. Dr. Hans Weber.
Uzticamība
Uz pierādījumiem balstīta interpretācija ar skaidriem turpmākās rīcības ceļiem, lai mazinātu trauksmi.